Clinical Trial: NCT05880706
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Sichuan Baili Pharmaceutical Co., Ltd. |
| Information Provided By: | Sichuan Baili Pharmaceutical Co., Ltd. |
| Last Update Posted: | 2025-09-19 |
Study Overview
Brief Summary
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
Official Title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: BL-B01D1
- Drug: Osimertinib Mesylate Tablets
Other Study ID Numbers
- BL-B01D1-203
Start Date (Actual)
2023-07-19
Primary Completion Date (Estimated)
2027-07
Study Completion Date (Estimated)
2027-07
Enrollment (Actual)
198
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Sichuan Baili Pharmaceutical Co., Ltd. |
| Information Provided By: | Sichuan Baili Pharmaceutical Co., Ltd. |
| Last Update Posted: | 2025-09-19 |
Study Overview
Brief Summary
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
Official Title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: BL-B01D1
- Drug: Osimertinib Mesylate Tablets
Other Study ID Numbers
- BL-B01D1-203
Start Date (Actual)
2023-07-19
Primary Completion Date (Estimated)
2027-07
Study Completion Date (Estimated)
2027-07
Enrollment (Actual)
198
Study Type
Interventional
Phase
Phase 2